Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Rhea-AI Summary

Nanobiotix announced its total outstanding shares as of February 28, 2022, amounting to 34,825,872, with total voting rights listed at 35,999,095 gross and 35,984,023 net. The company, listed on Euronext Paris and NASDAQ under symbol NBTX, focuses on developing innovative therapies targeting cancer and related health issues. With over 30 patents, its lead product NBTXR3 is authorized in Europe for soft tissue sarcoma treatment.

Positive

• 34,825,872 total outstanding shares enhances transparency.
• Total voting rights show significant investor engagement with gross at 35,999,095.
• Lead product NBTXR3 has received market authorization in Europe, indicating regulatory approval and commercial potential.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, gross (1)	Total voting rights, net (2)
February 28, 2022	34,825,872	35,999,095	35,984,023

⁽¹⁾ The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX: http://www.nanobiotix.com

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity.

The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, Switzerland, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

The company's resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at http://www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006210/en/

Nanobiotix

Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com



Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com



US – Porter Novelli

Dan Childs

+1 (781) 888-5106

dan.childs@porternovelli.com

Source: Nanobiotix

FAQ

What is the number of outstanding shares for Nanobiotix as of February 28, 2022?

As of February 28, 2022, Nanobiotix has 34,825,872 outstanding shares.

What are the total voting rights for Nanobiotix?

The total voting rights for Nanobiotix are 35,999,095 gross and 35,984,023 net.

What is the ticker symbol for Nanobiotix on NASDAQ?

The ticker symbol for Nanobiotix on NASDAQ is NBTX.

When was the market authorization for NBTXR3 obtained in Europe?

NBTXR3 was authorized for market use in Europe for treating soft tissue sarcoma, but the specific date is not mentioned in the PR.